VIDEO: Computerized test detects cognitive impairment, amyloid presence in preclinical AD
Click Here to Manage Email Alerts
PHILADELPHIA — A computerized cognitive battery was effective in detecting cognitive impairment and amyloid presence in preclinical Alzheimer’s disease, James E. Galvin, MD, MPH, said in this Healio Video Perspective.
Galvin and colleagues assessed the performance of Cognivue Clarity, a 10-minute, 10-subtest computerized testing battery, in 964 individuals enrolled in the Bio-Hermes study who were either diagnosed with mild cognitive impairment related to Alzheimer’s disease (AD), mild AD or healthy controls.
They presented their findings at the Alzheimer’s Association International Conference in Philadelphia.
The battery was administered alongside amyloid positron emission tomography, plasma amyloid/tau testing, ApoE genotyping, Mini Mental State Examination, the Functional Activities Questionnaire and Rey Auditory Verbal Learning Task.
Galvin noted that Cognivue Clarity was able to discriminate between healthy controls and those with mild AD symptoms, and detected the presence of AD pathology.
“Typically, this group is utterly undetectable using standard clinical measures,” said Galvin, professor of neurology and director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine, at AAIC. “The only thing to distinguish them is they have amyloid in their brain.”